Infectious Disease Control

Ebola disease in Democratic Republic of Congo: MSF scales up response to a rapidly evolving outbreak

HONG KONG, June 1, 2026 /PRNewswire/ -- In eastern Democratic Republic of Congo (DRC), people have been living through insecurity and with an under-resourced health system for years. The Ebola disease outbreak due to the Bundibugyo virus – which does not yet have approved vaccines or specific tre...

2026-06-01 18:06 3158

WuXi Vaccines' Drug Substance Facility Receives Brazil ANVISA GMP Certification for Dengue Vaccine Manufacturing

SUZHOU, China, May 26, 2026 /PRNewswire/ -- WuXi Vaccines, a wholly-owned subsidiary of WuXi Biologics, dedicated to vaccine Contract Development and Manufacturing Organization (CDMO), announced today that its drug substance facility (MFG23) located in Suzhou has received Good Manufacturing Pract...

2026-05-26 12:00 2976

Wincomm Secures Computex Best Choice Award for Three Consecutive Years (2024-2026), Leading the Future of AI-Powered Medical Solutions

HSINCHU, May 21, 2026 /PRNewswire/ -- Wincomm Corporation, a global leader in medical and industrial computing, is proud to announce it has achieved a prestigious milestone by winning the Computex Best Choice Award (BC Award) for three consecutive years from 2024 to 2026. This hat-trick of accola...

2026-05-21 15:16 4243

Advancing Influenza Vaccine Development: Sino Biological Launches Antigens for the 2026-2027 Northern Hemisphere Influenza Vaccine Strains

HOUSTON, March 3, 2026 /PRNewswire/ -- The World Health Organization (WHO) has announced its recommendations for the 2026–2027 Northern Hemisphere influenza vaccine composition, highlighting the continued spread of A(H3N2) subclade K and emerging B/Victoria lineage strains. In rapid response, Sin...

2026-03-04 09:53 6844

FDA Grants Breakthrough Device Designation to Two Rapid Tests Targeting Critical Drug-Resistant Pathogens

SANTA MARIA, Calif. and GUIPRY, France, Feb. 18, 2026 /PRNewswire/ -- In a major step forward against Antimicrobial Resistance (AMR), NG Biotech, in partnership with Hardy Diagnostics, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designations to...

2026-02-18 20:43 7823

CEPI and Samsung Biologics collaborate to strengthen outbreak-ready vaccine production and global access

OSLO, Norway and INCHEON, South Korea, Feb. 3, 2026 /PRNewswire/ -- The Coalition for Epidemic Preparedness Innovations (CEPI) and Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced a partnership to strengthen vaccine manufact...

2026-02-03 21:00 7996

Total Investment of Approx. USD 8.8 Million in Malaria, Tuberculosis, and NTD R&D Projects with Partners Including Mahidol University, Barcelona Institute for Global Health, and Eisai

TOKYO, Feb. 3, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.39 billion (USD 8.8 million1) in six R&D projects for the development of drugs, diagnostics and vaccines for malaria, tuberculosis (TB), and neglected ...

2026-02-03 09:00 6408

SK bioscience Initiates International Phase 1/2 Clinical Trial of Universal Vaccine Candidate Targeting Sarbecovirus Family

* Global phase 1/2 clinical trial initiated for GBP511, a vaccine targeting the Sarbecovirus Family * Next-generation vaccine leveraging SKYCovione's recombinant protein-based platform and nanoparticle technology * SK bioscience will continue to strengthen a Mid- to Long-Term global vaccine...

2026-01-29 10:10 7148

LakeShore Biopharma to Hold Extraordinary General Meeting of Shareholders

BEIJING, Jan. 20, 2026 /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("LakeShore Biopharma" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics f...

2026-01-20 20:00 8833

Hyundai Bioscience Confirms Entry into U.S. FDA Phase 2 Trials for Broad-Spectrum Antiviral 'XAFTY' Following 2026 Biotech Showcase Consensus

- UCSD's Dr. Davey Smith, former ACTIV-2 Protocol Chair, endorses 'Xafty' as "The weapon to end the virus war."  - Announces "One Drug, Two Tracks" strategy: Targeting Dengue in Vietnam and Respiratory Viruses (Flu, COVID, RSV) in the U.S. with the same drug.  - Dr. Davey Smith: "With this multi-v...

2026-01-15 11:34 6181

Global study targets dengue as disease threatens nearly half the world's population

LISMORE, Australia, Dec. 18, 2025 /PRNewswire/ -- Thousands of dengue forecasting models have been published, but few have been tested in real public-health settings. Now, researchers from the US andAustralia are launching a field evaluation inVietnam to see whether a new early-warning platform c...

2025-12-18 21:01 4361

GC Biopharma Ships First Doses of World's First Recombinant Anthrax Vaccine, 'BARYTHRAX inj.'

- First anthrax vaccine developed using recombinant DNA technology - Annual production capacity of up to 10 million doses at GC Biopharma's facility YONGIN, South Korea, Dec. 8, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a leading global biopharmaceutical company, today announced the first sh...

2025-12-08 14:36 2582

Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

TOKYO, Dec. 8, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today an investment of approximatelyJPY 70 million (USD 460,0001) for the development of a prototype detection test for mpox (formerly known as monkeypox2). Mpox is a viral infectious disease that h...

2025-12-08 09:00 1632

/C O R R E C T I O N -- Seegene Inc./

In the news release, "Seegene Establishes French Subsidiary to Expand European Footprint", issued05-Dec-2025 by Seegene Inc. over PR Newswire, we are advised by the company that the first sub-headline should read "France becomes Seegene's eighth overseas sales subsidiary and third inEurope, follo...

2025-12-06 00:00 4866

GC Biopharma's Varicella Vaccine Strain 'MAV/06' Listed in WHO Position Paper

* Officially recognized by WHO as a standard varicella vaccine strain alongside Oka * Interchangeability endorsed, enhancing global supply security YONGIN, South Korea, Dec. 2, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a global biopharmaceutical company, today announced that its propriet...

2025-12-02 13:00 2514

Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma Engineered with AI

SOLAIRIA-1 and SOLAIRIA-2 will evaluate GB-0895 in approximately 1,600 patients with severe asthma whose disease remains inadequately controlled on current therapies These are the first global Phase 3 studies of a long-acting anti-TSLP antibody, marking a pivotal step as GB-0895 advances the pro...

2025-12-01 19:00 2293

Healgen Scientific Spotlights the Rapid Check® COVID-19/Flu A&B Antigen Test to Help Families Stay Prepared for the Respiratory Virus Season

HOUSTON, Nov. 26, 2025 /PRNewswire/ -- As the holiday season approaches, gatherings among family and friends are expected to increase the risk of respiratory virus transmission, including COVID-19 and influenza. In response, Healgen® Scientific highlights the Rapid Check® COVID-19/Flu A&B Antigen ...

2025-11-27 00:00 1453

Total Investment of Approx. USD 11.6 Million in TB and NTD R&D Projects With Partners Including Fujifilm, Stop TB Partnership, and the Ohio State University

TOKYO, Oct. 29, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximatelyJPY 1.73 billion (USD 11.6 million1) in four R&D projects for the development of diagnostics and a vaccine for tuberculosis (TB), neglected tropical diseases...

2025-10-29 10:00 1664

Noul Supplies AI Diagnostic Platform miLab™ to Charité, Europe's Leading University Hospital

* Prestigious Nobel Prize–winning institution confirms adoption of miLab™ following clinical evaluation * "A milestone signaling broader adoption in advanced global healthcare markets" YONGIN, South Korea, Oct. 28, 2025 /PRNewswire/ -- Noul Co., Ltd.(CEO David Lim), an AI-driven blood and can...

2025-10-28 21:00 1842

Pfizer and BioNTech Receive Health Sciences Authority Approval for SARS-CoV-2 Sublineage LP.8.1-Adapted Monovalent COVID-19 Vaccine in Singapore

* The updated COVID-19 vaccine is expected to be available in Singapore at selected polyclinics and private general practitioner (GP) clinics inOctober 2025 for individuals 6 months of age and older. SINGAPORE, Oct. 24, 2025 /PRNewswire/ -- Pfizer Singapore and BioNTech SE (Nasdaq: BNTX, "BioNT...

2025-10-24 17:33 1893
12345 ... 36